Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin #1 [August 2018]

Product Code:
596201017
Publication Date:
August 2018
Format:
PDF
Price:
£910

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the submission of a Biologics License Application (BLA) to the FDA for Immunomedics’ sacituzumab govitecan for patients with metastatic triple-negative breast cancer (mTNBC); Puma Biotechnology’s Nerlynx (neratinib) receiving a positive opinion from the CHMP, recommending EU approval  for the extended adjuvant treatment of adult patients with early stage HR-positive, HER2 overexpressed/amplified BC; as well as Roche announcing that the Phase III IMpassion130 study, investigating Tecentriq (atezolizumab) plus chemotherapy as a first-line treatment for women with metastatic or unresectable locally advanced TNBC, met its primary endpoint.

Business Questions:

• How do KOLs view the BLA submission for sacituzumab govitecan for patients with metastatic triple-negative breast cancer?
• According to KOLs, how will sacituzumab govitecan be positioned?
• How do KOLs view results from a Phase I/II trial of sacituzumab govitecan in patients with advanced stage HER2-negative/ER-positive metastatic breast cancer?
• If approved in Europe, what uptake is Nerlynx (neratinib) expected to have according to KOLs?
• What do KOLs think of Tecentriq (atezolizumab) meeting the primary endpoint in the Phase III IMpassion130 trial?
• If approved, how do experts view Tecentriq’s positioning as a therapy for metastatic triple-negative breast cancer?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved